MX371276B - Soluciones de sidenafil y métodos para elaborar y usar las mismas. - Google Patents

Soluciones de sidenafil y métodos para elaborar y usar las mismas.

Info

Publication number
MX371276B
MX371276B MX2016012154A MX2016012154A MX371276B MX 371276 B MX371276 B MX 371276B MX 2016012154 A MX2016012154 A MX 2016012154A MX 2016012154 A MX2016012154 A MX 2016012154A MX 371276 B MX371276 B MX 371276B
Authority
MX
Mexico
Prior art keywords
methods
sildenafil citrate
making
same
sildenafil
Prior art date
Application number
MX2016012154A
Other languages
English (en)
Spanish (es)
Other versions
MX2016012154A (es
Inventor
Moshe Rogosnitzky
ABOOHI Morris
Original Assignee
Vigorous Solutions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX371276(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vigorous Solutions Ltd filed Critical Vigorous Solutions Ltd
Publication of MX2016012154A publication Critical patent/MX2016012154A/es
Publication of MX371276B publication Critical patent/MX371276B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q5/00—Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements
    • H01Q5/50—Feeding or matching arrangements for broad-band or multi-band operation
    • H01Q5/55—Feeding or matching arrangements for broad-band or multi-band operation for horn or waveguide antennas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/27—Adaptation for use in or on movable bodies
    • H01Q1/28—Adaptation for use in or on aircraft, missiles, satellites, or balloons
    • H01Q1/288—Satellite antennas
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/36—Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Astronomy & Astrophysics (AREA)
  • Remote Sensing (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Aviation & Aerospace Engineering (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2016012154A 2014-03-19 2015-03-19 Soluciones de sidenafil y métodos para elaborar y usar las mismas. MX371276B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461955299P 2014-03-19 2014-03-19
PCT/IB2015/052014 WO2015140748A2 (en) 2014-03-19 2015-03-19 Sildenafil solutions and methods of making and using same

Publications (2)

Publication Number Publication Date
MX2016012154A MX2016012154A (es) 2016-12-15
MX371276B true MX371276B (es) 2020-01-23

Family

ID=54145440

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012154A MX371276B (es) 2014-03-19 2015-03-19 Soluciones de sidenafil y métodos para elaborar y usar las mismas.

Country Status (24)

Country Link
US (2) US9968609B2 (da)
EP (2) EP3372083A1 (da)
JP (1) JP6744821B2 (da)
KR (1) KR20160137584A (da)
CN (1) CN106132204B (da)
AU (2) AU2015233006B2 (da)
CA (1) CA2942628C (da)
CL (1) CL2016002318A1 (da)
CY (1) CY1120187T1 (da)
DK (1) DK3119201T3 (da)
EA (1) EA032819B1 (da)
ES (1) ES2668915T3 (da)
HR (1) HRP20180773T1 (da)
HU (1) HUE038431T2 (da)
IL (1) IL247840B (da)
LT (1) LT3119201T (da)
MX (1) MX371276B (da)
NO (1) NO2723977T3 (da)
PL (1) PL3119201T3 (da)
PT (1) PT3119201T (da)
RS (1) RS57206B1 (da)
SG (2) SG11201607507VA (da)
SI (1) SI3119201T1 (da)
WO (1) WO2015140748A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2723977T3 (da) 2014-03-19 2018-03-10
JP6902372B2 (ja) * 2017-02-28 2021-07-14 ヱスビー食品株式会社 苦味抑制用組成物
AU2018397436A1 (en) * 2017-12-26 2020-08-13 Ftf Pharma Private Limited Liquid oral formulations for PDE V inhibitors
WO2020212931A1 (en) * 2019-04-18 2020-10-22 Vigorous Solutions Ltd. Liquid sildenafil citrate compositions
WO2021096871A2 (en) * 2019-11-12 2021-05-20 American Regent, Inc. Type v phosphodiesterase inhibitor compositions, methods of making them and methods of using them in preventing or treating elevated pulmonary vascular pressure or pulmonary hemorrhages

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426176T2 (de) * 1993-02-05 2001-04-05 Kao Corp., Tokio/Tokyo Verfahren zur geschmacksmodifizierung und verfahren zur verminderung eines bitteren geschmack
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
WO2001035926A2 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
JP2004500378A (ja) 2000-02-04 2004-01-08 ヨー、セオ、ホン 胆汁酸を含有する清浄水溶液製型の製造
AU2001273545A1 (en) 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US20030216407A1 (en) 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
WO2005046632A2 (en) 2003-11-17 2005-05-26 Patus Ltd. Compositions effective in altering the perception of malodor
CN1925860A (zh) * 2004-01-05 2007-03-07 特瓦制药工业有限公司 制备西地那非碱及其柠檬酸盐的方法
US7618976B2 (en) 2004-01-05 2009-11-17 Teva Pharmaceutical Industries Ltd Methods for the production of sildenafil base and citrate salt
US7727565B2 (en) 2004-08-25 2010-06-01 Cadbury Adams Usa Llc Liquid-filled chewing gum composition
PL1858488T5 (pl) 2005-03-14 2024-01-03 Wyeth Llc Kompozycje tygecykliny i sposoby wytwarzania
US7556487B2 (en) 2006-03-29 2009-07-07 Intergum Gida Sinayi ve Ticaret A.S. Apparatus for making center-filled chewing gum pieces
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
EP2008530B1 (de) 2007-06-19 2011-01-19 Symrise AG Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck
EP2072044A1 (en) * 2007-12-19 2009-06-24 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising a liquid or flowable core composition
WO2009125415A1 (en) 2008-04-07 2009-10-15 Hetero Research Foundation Amorphous form of sildenafil citrate
FR2939321B1 (fr) 2008-12-05 2011-08-26 Philippe Perovitch Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique.
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
DE102010049708A1 (de) * 2010-10-28 2012-05-03 Hexal Ag Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe
EP2787967B1 (en) * 2011-12-05 2018-10-31 Suda Limited Oral spray formulations and methods for administration of sildenafil
GB2497933B (en) 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
CN107929743B (zh) * 2012-01-18 2023-09-01 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
NO2723977T3 (da) * 2014-03-19 2018-03-10

Also Published As

Publication number Publication date
EA201691871A1 (ru) 2017-03-31
AU2015233006B2 (en) 2018-07-19
EP3119201A2 (en) 2017-01-25
IL247840B (en) 2019-03-31
HUE038431T2 (hu) 2018-10-29
EA032819B1 (ru) 2019-07-31
HRP20180773T1 (hr) 2018-06-15
US9968609B2 (en) 2018-05-15
US20170049776A1 (en) 2017-02-23
CN106132204B (zh) 2019-08-20
CA2942628C (en) 2022-06-07
LT3119201T (lt) 2018-05-10
CL2016002318A1 (es) 2017-03-24
CA2942628A1 (en) 2015-09-24
JP6744821B2 (ja) 2020-08-19
EP3372083A1 (en) 2018-09-12
AU2018250378A1 (en) 2018-11-08
PT3119201T (pt) 2018-06-15
SG10201808038TA (en) 2018-10-30
KR20160137584A (ko) 2016-11-30
PL3119201T3 (pl) 2018-08-31
DK3119201T3 (da) 2018-05-28
WO2015140748A3 (en) 2015-12-17
CY1120187T1 (el) 2018-12-12
SI3119201T1 (en) 2018-07-31
US20180233823A1 (en) 2018-08-16
MX2016012154A (es) 2016-12-15
AU2018250378B2 (en) 2020-05-14
EP3119201A4 (en) 2017-03-15
CN106132204A (zh) 2016-11-16
SG11201607507VA (en) 2016-10-28
RS57206B1 (sr) 2018-07-31
AU2015233006A1 (en) 2016-11-03
US10211534B2 (en) 2019-02-19
EP3119201B1 (en) 2018-03-14
WO2015140748A2 (en) 2015-09-24
JP2017508764A (ja) 2017-03-30
ES2668915T3 (es) 2018-05-23
NO2723977T3 (da) 2018-03-10

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
NZ729678A (en) Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist
MA39727A (fr) Compositions antimicrobiennes pour végétaux
MY191132A (en) Generation of peroxyformic acid through polyhydric alcohol formate
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX371276B (es) Soluciones de sidenafil y métodos para elaborar y usar las mismas.
MX2017008414A (es) Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas.
GB2540096A (en) Liquid concentrate of a strength retrogression additive
AU362552S (en) Swimsuit water extractor
AU358035S (en) Valve
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2017007577A (es) Compuestos de dihidropirimidin-2-ona y su uso medico.
GB2537519A (en) Magnesium metal ore waste in well cementing
MX2018007112A (es) Composicion de peroximonosulfato de disolucion rapida.
MX2019000677A (es) Células miméticas de células b.
PH12016502311A1 (en) Omega-3 analogues
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
CL2017000690A1 (es) Nuevo complejo hidróxido de hierro (iii) con jarabes de glucosa activados y procedimiento para su preparación
WO2017116903A8 (en) Method of preparing diaminophenothiazinium
RU2014119719A (ru) Применение препаратов на основе гумусовых веществ при производстве алкогольных напитков
AU201615391S (en) Dummy/pacifier
SA118390649B1 (ar) تخليق جسيمات نانوية من نوكسيا أوبوسيتيفوليا
GR1008534B (el) Παρασκευη και επεξεργασια και διατηρηση ελιας με ορυκτο αλατι ιμαλαϊων
WO2015003995A3 (de) Verfahren und vorrichtung zur bereitstellung einer hyaluronsäure enthaltenden zusammensetzung

Legal Events

Date Code Title Description
FG Grant or registration